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ABSTRACT
Over 30% of ERα breast cancer patients develop relapses and progress to 
metastatic disease despite treatment with endocrine therapies. The pioneer factor 
PBX1 translates epigenetic cues and mediates estrogen induced ERα binding. Here 
we demonstrate that PBX1 plays a central role in regulating the ERα transcriptional 
response to epidermal growth factor (EGF) signaling. PBX1 regulates a subset of 
EGF-ERα genes highly expressed in aggressive breast tumours. Retrospective 
stratification of luminal patients using PBX1 protein levels in primary cancer further 
demonstrates that elevated PBX1 protein levels correlate with earlier metastatic 
progression. In agreement, PBX1 protein levels are significantly upregulated during 
metastatic progression in ERα-positive breast cancer patients. Finally we reveal that 
PBX1 upregulation in aggressive tumours is partly mediated by genomic amplification 
of the PBX1 locus. Correspondingly, ERα positive breast cancer patients carrying 
PBX1 amplification are characterized by poor survival. Notably, we demonstrate that 
PBX1 amplification can be identified in tumor derived-circulating free DNA of ERα 
positive metastatic patients. Metastatic patients with PBX1 amplification are also 
characterized by shorter relapse-free survival. Our data identifies PBX1 amplification 
as a functional hallmark of aggressive ERα-positive breast cancers. Mechanistically, 
PBX1 amplification impinges on several critical pathways associated with aggressive 
ERα positive breast cancer.
INTRODUCTION
Over 30% of ERα positive breast cancer patients 
treated with endocrine therapies eventually relapse and 
progress into metastatic disease [1]. Previous studies 
strongly suggest that the endocrine therapy resistance 
and metastatic progression occur in a multi-step manner 
and are driven by genetic and epigenetic alterations 
[2–4]. Several evidences indicate that breast cancer 
growth becomes ultimately independent from ERα [5–8]. 
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Nonetheless this may be occurring toward the final stages 
of tumour progression. For instance, recent studies have 
discovered the existence of ERα activating mutations 
specifically in metastatic patients [9–12]. Additionally, 
ERα can be activated in the absence of estrogen by 
alternative mitogens including the epidermal growth factor 
(EGF) [13, 14]. EGF promotes ERα binding to thousands 
of regulatory elements and activates the transcription of 
a set of genes commonly over-expressed in the HER2 
subtype and associated with disease progression [15].
We have recently described the role of PBX1 
as a novel pioneer factor in ERα breast cancer [16]. 
PBX1 is critical to maintain chromatin accessibility and 
allow estrogen induced ERα recruitment to thousands 
of regulatory elements [16]. More importantly, 
we demonstrated that PBX1 is necessary for the 
transcriptional regulation of a subset of estrogen target 
genes directly associated with poor outcome. Furthermore, 
we have demonstrated that PBX1 upregulation is involved 
in the development of endocrine therapy resistance in vitro 
and that mRNA levels of genes controlled via Notch-
PBX1 crosstalk are associated with poor prognosis in 
ERα patients [5]. Whether PBX1 contributes to estrogen-
independent, EGF driven activation and recruitment 
of ERα is not yet known. We have thus investigated 
the role of PBX1 in mediating EGF signalling in ERα 
positive breast cancer cell lines using genome wide-
analyses including microarray and ChIP-seq. Our 
results demonstrate that PBX1 is required to direct 
EGF-ERα signalling at the chromatin level in breast 
cancer cells. PBX1 is also required for the expression 
of genes associated with tumour progression. PBX1 
protein levels were significantly upregulated in vivo in 
metastatic samples from patients treated with endocrine 
therapies. Analysis of an independent historical collection 
of primary samples demonstrated that PBX1 protein 
levels correlate with shorter time to progression in ERα 
patients. Finally, we present evidences suggesting that 
PBX1 may be amplified in over 10% of ERα positive 
breast cancer patients and amplification is associated with 
shorter survival. PBX1 amplification was confirmed in 
the circulating free DNA (cfDNA) of metastatic patients 
further suggesting the potential for using PBX1 to monitor 
breast cancer progression.
RESULTS
PBX1 mediates EGF signaling in ERα positive 
breast cancer cells
We recently demonstrated that PBX1 is a pioneer 
factor in ERα-positive breast cancer, occupying the 
chromatin prior to ERα binding following its activation 
with estrogen and regulating the expression of estrogen 
dependent genes associated with aggressive progression 
[16]. In addition we showed that ERα controls a different 
transcriptional program when activated by growth factors 
[15]. Specifically, EGF can activate ERα via serine 
phosporylation and promotes transcription of genes 
associated with aggressive HER2 positive tumours [15]. 
Therefore, we reasoned that PBX1 might also play a 
role in estrogen independent EGF driven ERα induced 
transcription. ERα-positive MCF7 cells proliferate 
in response to EGF when cultured in the absence of 
estrogen and this phenotype is dependent on ERα [15]. 
PBX1 depletion using two siRNA molecules is sufficient 
abrogate the proliferative response induced by EGF 
suggesting that PBX1 regulates EGF-ERα signaling 
(Fig. 1A–1B). Similar results were also obtained using 
T47-D, a second independent ERα-positive breast cancer 
cell line (Fig. S1A). We and others have previously 
showed that PBX1 is a direct Notch target that can be 
potentially antagonized with gamma secretase inhibitors 
(GSI, MRK003 and PF03084014) [5, 17]. In agreement, 
treatment with MRK003 is sufficient to downregulate 
PBX1 at mRNA and protein levels (Fig. S1B–S1C) and 
suppresses EGF induced proliferation in MCF7 cells 
(Fig. S1D–S1E). EGF activates ERα by promoting 
receptor phosporylation at several key residues via AKT 
signaling pathway [15], including S118 [18]. Notably, 
PBX1 silencing did not impair ERα phosphorylation 
suggesting that defects in EGF induced proliferation did 
not stem from defect in non-canonical activation of ERα 
[19] (Fig. S2A). However, growth deficit in response to 
GSI treatment might stem from a combination of PBX1 
downregulation and direct inhibition of EGF signalling 
(Fig. S2A).
Next, we investigated the transcriptional effect 
of PBX1 silencing on the EGF-ERα transcriptional 
program using qRT-PCR. As expected, silencing PBX1 
in MCF7 cells impaired the transcriptional activation of 
a known set of EGF-ERα target genes [15] (Fig. 1C). 
These results were confirmed and expanded using 
expression microarrays (Fig. 1D). Our data indicate that 
over 60% (252 out of 383) of the genes differentially 
expressed in response to EGF signaling require PBX1 
for their regulation (Fig. 1D and Table S1). These data 
are strongly reminiscent of our previous finding in which 
a subset of estrogen responsive genes were dependent 
on PBX1 [16]. PBX1 dependent genes were enriched 
for several important ontological terms associated with 
breast cancer and endocrine therapy resistance, including 
Notch signaling, pro-invasive signaling and epithelial and 
mammary carcinoma (Fig. 2). Interestingly, genes that 
failed to be induced by EGF in PBX1 depleted cells are 
also significantly enriched in several independent genes 
datasets obtained from patients characterized by aggressive 
breast cancers (Fig. S2B). Overall, these data suggest that 
PBX1 underlies the expression of EGF dependent genes 
involved in aggressive tumour progression.
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PBX1 is pre-loaded at regulatory elements 
recruiting ERα during EGF signaling
Pioneer factors such as PBX1 and FOXA1 bind to 
the chromatin prior to ERα recruitment where they are 
thought to mediate or maintain chromatin accessibility 
[20–22]. To determine if PBX1 could serve as a pioneer 
factor for ERα under EGF stimulation we conducted ChIP-
seq assays in MCF7 cells. We then compared the EGF-ERα 
cistrome (e.g. ERα genome wide binding sites induced 
upon EGF stimulation) with the estrogen-ERa cistrome 
and previously published PBX1 cistrome. In agreement 
with previous reports [15], most ERα chromatin binding 
is unique to specific stimuli (EGF-ERα vs. E2-ERα) 
(Fig. 3A and S3A). PBX1 occupies approximately 30% 
of ERα binding sites, regardless of the stimulus (Fig. 3A). 
PBX1 binding occurs prior and is not affected by EGF 
stimulation as demonstrated by direct ChIP-qPCR assays 
at selected binding sites in proximity of EGF regulated 
genes (Fig. 3B). This process is strongly reminiscent of 
PBX1 behaviour in the context of estrogen stimulation 
[16]. We next considered if EGF induced ERα binding 
sites that overlap with PBX1 have a functional relationship 
with the EGF-ERα transcriptional program. To do this 
we have combined transcriptional and ChIP-seq data of 
MCF-7 cells treated with EGF. We have analysed genes 
whose expression changed in response to EGF stimulation 
(all upregulated genes) for enriched binding patterns near 
their transcriptional starting site (up to 20 kb upstream 
of the TSS). We focused on ERα binding in response to 
estrogen (17 beta-estradiol, E2) or EGF with or without 
concurrent PBX1 and FOXA1 binding. Our data show 
that genes that respond to EGF are significantly enriched 
for PBX1-EGF-ERα binding but lack PBX1-E2-ERα 
binding sites (Fig. S3B, red dots). FOXA1 binding was 
less enriched near these genes (Fig. S3B, light-blue dots). 
Figure 1: PBX1 is required to activate EGF signaling in ERα breast cancer cells. A. PBX1 silencing using two independent 
siRNAs B. Proliferation curves in response to EGF stimulation (100 ng/ml) or mock control in MCF7 cells. C. Transcriptional activation 
of several EGF target genes is lost upon PBX1 depletion. The fold induction was calculated averaging three independent experiments. All 
comparison between siRNA and control are statically significant (Student’s t-test, p < 0.05) D. Microarray analysis of PBX1 depleted cells 
demonstrates that PBX1 control a large portion of EGF dependent genes. Asterisks identify significant differences between treatments.
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EGF responsive genes are also significantly enriched for 
PBX1-FOXA1-non specific ERα binding, suggesting that 
co-activation may also play an important role to regulate 
this subset of genes (Fig. S3, purple dots). As expected, 
regions pre-bound by pioneer factors that did not recruit 
ERα lacked any association with transcription. Collectively, 
these analyses confirm that PBX1 binding is directly 
involved in regulating EGF-ERα signaling in MCF-7 cells.
We have previously demonstrated that H3K18ac can 
be used to detect stimuli specific co-activation (EGF vs. 
E2) at regulatory regions in which ERα binding occurs 
under both treatment [15]. Interestingly PBX1 depletion 
directly suppressed H3K18ac signal at several putative 
elements normally recruiting ERα (Fig. 3C). Globally, 
PBX1-EGF-ERα regions are characterized by open 
chromatin status as demonstrated by FAIRE-seq and 
DNaseI-hypersensitivity-seq assays (Fig. 3D). However, 
PBX1 depletion results in a significant decrease in 
chromatin openness (as demonstrated by reduced FAIRE 
signal) at several regions associated with EGF-ERα target 
genes suggesting that PBX1 modulates ERα signaling by 
influencing the chromatin environment.
PBX1 is a novel luminal breast cancer prognostic 
biomarker
Our mechanistic study revealed that PBX1 controls 
the expression of a subset of ERα target genes stimulated 
Figure 2: PBX1 controls the expression of genes associate with breast cancer progression. Genes whose failed to be 
upregulated by EGF upon PBX1 silencing (n = 147) were used for ontology analysis using GREAT [48].
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Figure 3: PBX1 regulate chromatin status at EGF-ERα binding sites. A. ChIP-seq analysis of PBX1 and ERα in MCF7 cells 
B. ChIP-qPCR validation of PBX1 binding at potential regulatory EGF-ERα binding sites in the absence of EGF stimulation. CTRL 
indicate stimulation using mock. The fold enrichment was calculated averaging three independent experiments. All comparison between 
siRNA and control are not statically significant (Student’s t-test, p < 0.050) C. PBX1 silencing abrogates epigenetic co-activation of EGF-
ERα regulatory elements as measured by induced H3K18 acetylation. The fold enrichment was calculated averaging three independent 
experiments. All comparison between siRNA and control are statically significant (Student’s t-test, p < 0.050) D. Genome wide chromatin 
accessibility analyses at PBX1 and EGF-ERα shared sites. E. PBX1 depletion negatively impact chromatin accessibility at EGF-ERα 
binding sites as identified by reduced FAIRE signal.
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by EGF in vitro and may be linked to breast cancer 
progression. Furthermore we previously demonstrated 
that PBX1 displays an analogous function by controlling 
a subset of estrogen induced genes strongly associated 
with poor prognosis [16]. In light of these observations 
we hypothesized that PBX1 expression levels could 
contribute to breast cancer progression in ERα positive 
breast cancer patients. To test this hypothesis we 
performed meta-analysis on METABRIC (Illumina 
arrays) and The Cancer Genome Atlas (TCGA, RNA-
seq data) studies stratifying ERα-positive breast cancer 
patients in high and low PBX1 expressors. In both 
datasets high PBX1 mRNA levels correlate with shorter 
survival (Fig. S4A). For the METABRIC dataset, 
PBX1 expression retained significance in a multivariate 
analysis including lymph node status, grade and tumor 
size (HR = 1.27, p = 0.0173). For the TCGA datasets 
the TNM status was published for each patient. In the 
multivariate analysis including PBX1, T, N and M, PBX1 
reached the highest significance (p = 0.041, HR = 7.82), 
M also reached significance (p = 0.045, HR = 2.89) while 
T and N were not significant. These correlations were not 
significant in ERα-negative breast cancer patients further 
supporting the notion that PBX1 is a key regulator of ERα 
activity (Fig. S4A). Notably, higher PBX1 levels were 
significantly associated with poor prognosis in a subset 
of patients treated with endocrine therapy (Fig. S4B). 
Again, PBX1 retained significance in a multivariate 
analysis including lymph node status, grade, tumor 
size and PBX1 expression (HR = 1.27, p = 0.0173). To 
elucidate further the potential role of PBX1 as a breast 
cancer biomarker, we tested the association between its 
expression and metastatic progression in an additional 
six independent studies (Affymetrix arrays). Overall, 
PBX1 expression was associated with increased risk in 
metastatic progression (HR 1.47, p < 0.008, n = 674). 
We found more variability within the individual cohorts, 
however, statistical significance was reached only for 
datasets in which PBX1 represents a poor prognostic 
marker (Fig. S5). Additionally, multivariate analysis in 
the grouped cohort indicates that PBX1 prognostic power 
is independent from Ki67 (p < 0.0001)
To confirm these findings we measured PBX1 
protein levels using IHC in longitudinal clinical samples. 
We collected 20 biopsies from primary ERα-positive 
breast cancers and compared PBX1 protein levels with 
matched relapses (all endocrine treated, average time to 
relapse = 44.4 ± 35 months). We stained all sections using 
a validated antibody (Fig. S1C and S2A) [5, 16] and scored 
each sample based on PBX1 nuclear intensity (Fig. 4A). 
Remarkably, metastatic samples had a significant increase 
in H score compared to the original primary biopsies 
confirming PBX1 upregulation in drug-resistant metastatic 
patients (Fig. 4A). Finally, we investigated PBX1 protein 
levels in the Tenovus Nottingham cohort of FFPE primary 
breast cancers (n = 1650) [23]. In agreement with cell 
line data, we found that PBX1 protein levels significantly 
correlate with ERα, FOXA1 and GATA3 (another 
important ERα pioneer factor [22]) thus demonstrating that 
PBX1 is strongly associated with ERα-positive, luminal 
breast cancer subtypes (Fig. 4B). We therefore restricted 
further analysis to ERα positive breast cancer patients. 
Since PBX1 protein levels were dramatically increased in 
metastatic samples, we hypothesized that high levels of 
PBX1 in primary samples might identify patient at higher 
risk of relapse. Our results show that ERα-positive breast 
cancer patients with elevated PBX1 staining intensity at 
diagnosis (over 90% positive staining) develop metastatic 
disease significantly faster than patients with lower 
staining intensity (Fig. 4C). Overall this data strongly 
suggest that PBX1 protein levels in primary breast cancer 
are significantly associated with breast cancer progression.
PBX1 locus is amplified in patients with 
aggressive ERα breast cancer
Our analysis using PBX1 transcriptional and protein 
levels strongly supports the role of PBX1 as a functional 
biomarker associated with ERα breast cancer progression 
(Fig. 4 and S4–S5). PBX1 transcripts are significantly 
overexpressed in breast cancer when compared to normal 
tissues (Fig. S6). For example, PBX1 ranks in the top 50 
most overexpressed genes in ductal and lobular carcinoma 
compared to normal tissue in TCGA cohort (dataset 30 
in Fig. S6) [24]. Similarly, PBX1 ranks in the top 4% of 
the most overexpressed transcripts in the METABRIC 
cohort (Invasive Ductal vs. Normal, dataset 7, Fig. S6) 
[25]. To the best of our knowledge, there is no indication 
in the literature that PBX1 is required for normal breast 
development. In agreement, we found that normal ductal 
cells adjacent to tumor tissue have very low PBX1 staining 
(stronger stained cells are myoepithelial cells, Fig. S7). 
Thus, PBX1 expression seems to be a major determinant 
for the development and progression of luminal breast 
cancer patients.
Recent tumour sequencing efforts indicate that 
PBX1 locus is potentially amplified in 13% of primary 
breast cancers (TCGA provisional) (Fig. S8A) [26] 
supporting the hypothesis that genomic amplification 
may partially explain PBX1 overexpression in breast 
cancer (TCGA provisional) (Fig. S8B). Of note, within 
the published TCGA dataset [24], PBX1 potential 
amplification strongly correlates with higher mRNA 
levels in ERα-positive but not in ERα-negative breast 
cancer patients (Fig. S9). These data suggest that PBX1 
copy number variation (CNV) might then be functional 
only in ERα-positive breast cancer patients. We then 
identified the TCGA patients (TCGA provisional) with 
ERα-positive disease that had at least 3 copies of PBX1 
(95/1145, 8.3%) and analysed the proportion of patients 
with lymph-node micro-metastasis. Strikingly, we found 
that 60% of patients with PBX1 amplification had at 
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least one positive lymphnodes vs. 38.7% of the control 
group (Fisher exact test 7.3* 10−5). Conversely, PBX1 
amplification correlates, although not significantly, with 
a lower chance of metastatic disease in the limphnodes 
in ERα negative breast cancer patients (45% vs. 57% 
respectively).
Figure 4: PBX1 is a novel prognostic biomarker for ERα breast cancer. A. Primary and matched Metastatic samples from the 
Imperial College TMA were processed using PBX1 IHC and H score were plotted. Pair-wise T-test between the average score (3 independent 
scorer, duplicate sections) was used to establish significance B. Core primary biopsies in the Tenovus Nottingham cohort show different 
level of staining by PBX1 IHC. PBX1 correlates with several important clinico-pathological parameters including hormone status and ERα 
associated pioneer factors. C. Survival analysis (Log-rank Mantel-Cox test) was performed looking at patients with very high PBX1 levels 
versus the remaining patients. Analysis was restricted to the to the ERα positive population.
Oncotarget8www.impactjournals.com/oncotarget
We then restricted our analysis to ERα positive 
breast cancer patients from the published TCGA data 
to exploit the more complete clinical annotations [24] 
and found that 28/364 (8%) carried potential PBX1 
amplification/overexpression (Fig. 5A). Patients with 
putative PBX1 amplification had a median survival of 
30.98 months compared to 113.74 (PBX1 Amplified vs. 
Not Amplified in Luminal patients, P < 10−5) (5A). On the 
other hand, PBX1 amplification did not reach prognostic 
significance in ERα negative patients (however, only 
Figure 5: PBX1 amplification is a prognostic biomarker for ERα breast cancer. A. TCGA luminal patients [24] were stratified 
based on putative PBX1 amplification and overall survival was calculated B. The same analysis was repeated in basal and claudin low 
patients C. qPCR measurement of PBX1 genomic DNA in cfDNA from primary and metastatic ERα breast cancer patients E–F. Metastatic 
patients from panel C were stratified based on PBX1 amplification and Time to relapse and Overall survival were calculated. Groups were 
compared using a Log-rank Mantel-Cox test.
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6% of patients carries amplification) (Fig. 5B). When 
we looked at genes potentially co-amplified with PBX1 
(chr1q23.3) [27] we found that very few candidates were 
also over-expressed in breast cancer (Fig. S10A). More 
importantly, PBX1 was one of the only two transcripts 
(the other being PVRL4) carrying evidence of prognostic 
significance in the ERα-positive breast cancer subtype 
(METABRIC) (Fig. S10B).
We then considered the possibility of using PBX1 
CNV as a proxy for PBX1 protein levels. Potentially, this 
would allow for monitoring PBX1 levels by measuring 
its amplification in DNA derived from cancer cells using 
non-invasive methods. The tumour derived fraction 
of circulating free-DNA (cfDNA) originating from 
tumour cells can be used to estimate the genomic status 
of breast cancer lesions [28–30]. We then measured 
PBX1 amplification using a qPCR assay in cfDNA 
from 37 patients with ERα-positive primary disease 
and 50 patients with ERα-positive metastatic disease 
treated with endocrine therapy (Table S2). We could not 
identify significant CNV in blood from primaries ERα-
positive breast cancer patients. However, we identified 
5/50 (10%) patients with PBX1 amplification (RQ > 2) 
and two patients with probable allelic loss (4%) in the 
metastatic cohort (Fig. 5C). We then reasoned that the 
emergence of PBX1 CNV may have contributed to tumor 
progression and used PBX1 amplification in cfDNA as a 
classifier to stratify patients based on time to relapse or 
overall survival. In this small cohort, PBX1 amplification 
was significantly associated with earlier metastatic 
relapse (p < 0.035, HR 5.95, Cox- Mantel-Test) (Fig. 5D). 
These data are in strong agreement with our protein and 
transcriptional tumour profiling and coupled with our 
mechanistic study demonstrate that PBX1 plays a crucial 
role in ERα-positive breast cancer development and 
progression.
DISCUSSION
Our work has identified PBX1 as a novel functional 
biomarker in ERα positive breast cancer. We have 
identified a mechanistic association between PBX1 and 
ERα recruitment in response to EGF signaling. We also 
established the significance of PBX1 mRNA and protein 
level as a prognostic biomarker in several independent large 
cohorts of primary breast cancers. Notably, PBX1 levels are 
strongly associated with metastatic progression. Finally, we 
demonstrate that the longitudinal increment of PBX1 levels 
observed throughout cancer progression are partly due to 
genomic events that could be potentially used to monitor 
disease progression in patients by non-invasive assays.
The number of signaling molecules potentially 
involved in breast cancer is rapidly increasing. In this 
context, ERα remains a central hub required to regulate 
and integrate signaling at the chromatin level [31, 32]. 
EGF signaling cascade partially converge on ERα in breast 
cancer cells where it provides for an additional survival 
pathways. ERα target genes induced via classical estrogen 
signaling and non-canonical EGF signalling are quite 
distinct [14, 15]. Nonetheless, PBX1 remains a common 
denominator of these two pathways via its conserved 
interaction with ERα. It will be interesting to investigate 
the role of pioneers factors in alternative ERα pathways, 
including metabolic induced ERα signaling [33, 34]
Genetic aberration targeting chromatin remodelers 
and other proteins involved in epigenetic processes are 
now frequently recognized as major drivers in several 
types of cancers [35]. Synergy between epigenetic and 
genetic drivers may be particularly important in breast 
cancer considering the essential role of ERα in these 
malignancies and the intimate crosstalk between ERα and 
the chromatin [21, 22, 36]. For example, it is possible that 
PBX1 overexpression may lead to an increased number of 
chromatin accessible sites thereby allowing ERα binding 
near oncogenes [37]. While several other pioneer factors 
play a central role in modulating ERα binding in breast 
cancer cells [16, 22, 36, 38, 39], our data suggest that 
PBX1 has some unique properties. For example, FOXA1 
[39] and GATA3 [40] play a central role in mammary 
and ductal morphogenesis and their interaction with ERα 
can be regarded as developmentally conserved [41, 42]. 
On the other hand PBX1 expression is restricted to ERα 
transformed cells and practically absent in normal ductal 
cells. In addition, FOXA1 and GATA3 are frequently 
targeted by mutations in breast cancer [43] (Fig. S11), 
while PBX1 is rarely affected by somatic mutations 
(V117M and H425N, 2 out of 892 patients). Furthermore 
FOXA1 and GATA3 are frequently downregulated in basal 
tumour but rarely over-expressed or amplified in luminal 
cancer (Fig. S11) [44] while PBX1 is among the top 
upregulated genes and is frequently amplified in luminal 
cancers (Figs. 4–5, S6, S8, S10 and S11).
Despite the impossibility to elucidate the temporal 
details of PBX1 amplification/overexpression, our 
data strongly suggest that PBX1 upregulation may 
contribute to breast cancer progression and metastatic 
development. Clonal evolution is thought to contribute 
significantly to cancer progression [45]. In this context, 
we can envision two possible models: in the first, cells 
carrying PBX1 amplification may be more adapted to 
escape the primary site and colonize distal tissues. On 
the other hand, it is possible that endocrine therapies 
exert positive selective pressure on cells that incur in 
Chr1q23.3 gains. In both scenarios, it is tempting to 
speculate that PBX1 would contribute to epigenetic 
reprogramming by interpreting or shaping the histone 
modifications landscape [21]. Ultimately, these changes 
would modulate ERα signaling and allow breast cancer 
cells to have an increased fitness in response to a diverse 
array of signalling pathways.
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MATERIALS AND METHODS
Cell lines
MCF-7 and T47D cells were cultured and 
maintained as previously described [16]. EGF stimulation 
was performed as previously described [15]. Proliferation 
curves were performed as previously described [16]. 
Treatment with GSI (10uM of MRK003 or PF03084014) 
was performed as previously described [5]. Experiments 
were repeated independently at least five times.
RT-qPCR and microarray
RNA samples from siControl or siPBX1 treated 
MCF7 in the presence or absence of EGF were extracted 
with RNAeasy (Quiagen) and retro-transcribed with 
iSCRIPT (Biorad). For microarrays, RNAs were hybridized 
on HT12 human beads array (Illumina Inc.). Analyses 
were performed using BRB- Array Tools Version 3.8.1. 
Raw intensity data were log2 transformed, median 
normalized and filtered to remove non- detected spots 
as determined by Illumina Software. The normalization 
was performed by computing a gene-by-gene difference 
between each array and the median (e.g. reference) 
array, and subtracting the median difference from the 
log intensities on that array, so that the gene-by-gene 
difference between the normalized array and the reference 
array is zero. Two class non-paired comparison analyses 
were performed by computing a t-test for each gene using 
normalized log-intensities. Differentially expressed genes 
were determined at a significance level of q less than 
0.01. A four class ANOVA at p less than 0.01 was also 
performed to identify genes expressed differentially across 
the four groups. Hierarchical clustering was employed by 
calculating Euclidean distance to generate heat maps for 
subsets of significant genes using the open source software 
Cluster/Treeview.
ChIP and ChIP-seq
ChIP assay were conducted as described previously 
described using PBX1 (Abnova, M01 clone 4A2) or ERα 
(Santa Cruz biotechnology) [16] using 5–10* 106 cells. 
Library preparation for next-generation sequencing 
was performed according to manufacturer’s instruction 
starting with 5 ng of material (Illumina Inc.). Single 
paired libraries were sequenced using the HT2500 
(Illumina Inc). Over 20 million 50 bp reads were 
generated through for the ERα ChIP and Input samples. 
Of those, over 92% were aligned to the human reference 
genome. These reads were aligned using bowtie [46] 
(default setting). The MACS peak-calling algorithm was 
used to call significantly enriched peaks using default 
settings (P < 10–5) [47].
Ontology analysis and heatmap analysis
Ontology analyses were performed using GREAT 
[48]. Heatmaps were generated using CHASE [49].
Imperial tissue microarray of paired primary 
and secondary breast cancers
Twenty primary breast carcinomas with a paired 
metastasis were acquired from the pathology archives 
of Charing Cross Hospital, London, UK. A tissue 
microarray was constructed using a manual microarrayer 
(Beecher) and 0.6 mm punches. The tissue microarray 
was immunohistochemically profiled for PBX1 and 
other biomarkers as previously described [16]. PBX1 
monoclonal antibody (Abnova, (M01), clone 4A2) was 
optimized to a working concentration using tissue sections 
(5 μm). Antigen retrieval was performed using 10mM 
Tris-HCl with 1 mM EDTA (pH 9.0), heated in a water 
bath at 95°C for 30 min followed by cooling at room temp 
for 30 min. Blocking was done using 0.3% hydrogen 
peroxide in PBS, followed by normal goat serum (20 μl 
per ml) for 30 min. The primary antibody (1:50 in PBS) 
was incubated overnight at 4°C, then detected using anti-
rabbit secondary antibody, Vectastain Elite peroxidase 
ABC kit, and ImmPACT DAB kit (all from Vector 
Laboratories). Subsequently, immunohistochemistry was 
performed on TMA sections (4–5 μm) using the optimized 
staining protocol, including negative controls (omission 
of the primary antibody). PBX1 immunoreactivity was 
localized in the nucleus. Staining was scored based on the 
H-score and Allred Quick score (LM, DKP and PV).
Nottingham tenovus primary breast 
cancer series
Primary operable breast cancer cases (n = 1650) 
from the Nottingham Tenovus Primary Breast 
Carcinoma Series were used and were utilized for 
immunohistochemistry. Clinical data were maintained 
on a prospective basis with a median follow-up of 
126 months [23, 50]. The tissue microarrays and full-face 
sections form the Nottingham Tenovus Primary breast 
cancer series were immunohistochemically profiled 
for PBX1 and other biological antibodies as previously 
described. PBX1 mouse monoclonal antibody (Abnova, 
(M01), clone 4A2 [16] was optimized to a working 
concentration, utilizing μm matched full- face excisional 
tissue sections. Antigen retrieval was performed using 
Leica ER2 (pH 9.0) retrieval solution, water bath at 95C 
for 35 minutes followed by TBS at 50C for 10minutes. 
Blocking was done using Thermo Fisher UltraV block 
5mins. Antibody concentration was 1:50 overnight at 
4°C. Subsequently, 4 μm TMA sections were immuno-
stained using the optimized staining protocol. Detection 
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was achieved using the Novalink Polymer Detection kit 
(Leica Micro- systems Inc., USA). Negative controls 
were performed by omission of the primary antibody. 
IHC revealed that PBX1 had a nuclear location (4B). 
Nuclear staining was scored based on the H-score and 
Allred Quick score. Determination of the optimal cut-offs 
was per- formed using histograms and confirmed using 
X-tile bio-informatics software (Yale University, USA) 
[51] where data were split into training and validation 
sets. A total of 1198 tumours were suitable for analysis 
(460 PBX1 negative and 738 PBX1 positive). The tumour 
cores were evaluated by two of the coauthors (DKP 
and PV) blinded to the clinico-pathological characteristics 
of patients. There was substantial intra- and inter- observer 
agreement (k [0.768; Cohen’s j and multi-rater j tests, 
respectively).
Survival analysis using transcriptomics data
Positive PBX1 expression was dichotomised to 90% 
using distant metastases as an outcome and determined 
through X-tile software (University of Yale, Yale, USA) 
[51]. Prognostic analyses were undertaken using Kaplan-
Meier curves using the Log-rank test. A p-value < 0.05 
was considered significant.
Survival analysis using transcriptomics data
Database construction and survival analysis was 
performed as described previously [52]. For the expression 
of the genes, the median expression was used as the cut-
off in a Cox regression analysis. Kaplan-Meier survival 
plot, and hazard ratio with 95% confidence intervals and 
logrank P value were calculated and plotted in R using 
Bioconductor packages.
Construction of METABRIC microarray 
database
The Metabric project employed Illumina 
microarrays to measure gene expression across all genes. 
The raw gene chip files were downloaded from the 
European Genome-phenome Archive (EGA) (https://
www.ebi.ac.uk/ega/) [25]. The entire cohort contains 1988 
samples, the average overall survival is 8.07 years, 76% of 
the samples are ER positive and 47.3% are node positive. 
Due to batch effects between the Metabric training and 
validation sets we have not used the pre-normalized tables 
but have re-run the complete pre-processing for all arrays. 
In this, raw data was first imported into R and summarized 
using the beadarray package [53]. For annotation, 
the Illumina Humanv3 database of Bioconductor was 
used (http://www.bioconductor.org). Finally, quantile 
normalization was performed using the preprocessCore 
package [54].
FAIRE and DNaseI-hypersensitivity-seq
FAIRE-seq and DHS-seq analysis were performed 
as previously described [16, 55] with minor modifications.
Circulating free DNA analysis
DNA was extracted from blood cell pellets and 
1ml plasma as described previously [30]. To confirm 
amplification of PBX1, 10ng cfDNA was subjected 
to 5 cycles of preamplifcation with a mix of primers 
(including PBZ1 and reference genes). Each sample was 
then analysed in triplicate by real-time quantitative PCR 
(qPCR) in a 10 μl reaction volume. Reactions were run on 
an Applied Biosystems thermal cycler (Step One Plus) and 
analysed with Step One v2.1 software and Microsoft Excel.
Primers
Primers sequences (RT-qPCR, ChIP-qPCR) 
are available upon requests. Primers to study PBX1 
amplification were as follow: Primers PBX1-F: 
AGCCCACTCATCTTACGTGAC PBX1-R: 
ACGAAATTCCACTCCAACTCCA Probe PBX1 
GCTCAGGCCTATCTTCTGGA FAM-MGB
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